Current understanding of the neurobiology of major depressive disorder.

Depression is highly prevalent worldwide and associated with significant morbidity and mortality. Approximately 340 million people worldwide suffer from depression at any given time. Based on estimates from the World Health Organization (WHO), depression is responsible for the greatest proportion of burden associated with non-fatal health outcomes and accounts for approximately 12% total years lived with disability. Probably no single risk factor can be completely isolated in major depressive disorder (MDD), as interactions between many sources of vulnerability are the most likely explanation. Buttressing the identification of grief, demoralization, hopelessness and styles of psychological coping of the depressed patient are vital, ongoing scientific developments that flow from an increased understanding of this interplay amongst the immune system, endocrine system and brain. The rapidly accumulating body of neurobiological knowledge has catalyzed fundamental changes in how we conceptualize depressive symptoms and has important implications regarding the treatment and even prevention of depressive symptoms in patients.

[1]  Philip D. Harvey,et al.  New insights into the link between cardiovascular disease and depression , 2007, International journal of clinical practice.

[2]  An-Li Wang,et al.  MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats. , 2009, Behavioral neuroscience.

[3]  B. Thierry,et al.  The tail suspension test: A new method for screening antidepressants in mice , 2004, Psychopharmacology.

[4]  R. Belmaker,et al.  Major depressive disorder. , 2008, The New England journal of medicine.

[5]  S. Dunnett,et al.  Cognitive dysfunction and depression in Parkinson’s disease: what can be learned from rodent models? , 2012, The European journal of neuroscience.

[6]  A. Beck.  The evolution of the cognitive model of depression and its neurobiological correlates. , 2008, The American journal of psychiatry.

[7]  Bruce McEwen,et al.  Gender differences in age-related changes in HPA axis reactivity , 2001, Psychoneuroendocrinology.

[8]  Y. Ho,et al.  Effects of d-cycloserine on MPTP-induced behavioral and neurological changes: Potential for treatment of Parkinson's disease dementia , 2011, Behavioural Brain Research.

[9]  S. Hyman,et al.  Animal models of neuropsychiatric disorders , 2010, Nature Neuroscience.

[10]  H. Christensen,et al.  Modifiable risk factors predicting major depressive disorder at four year follow-up: a decision tree approach , 2009, BMC psychiatry.

[11]  P. Sullivan,et al.  Genetic epidemiology of major depression: review and meta-analysis. , 2000, The American journal of psychiatry.

[12]  E. Nestler,et al.  Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action , 2006, Nature Neuroscience.

[13]  John Suckling,et al.  Neural responses to happy facial expressions in major depression following antidepressant treatment. , 2007, The American journal of psychiatry.

[14]  W. Drevets,et al.  The Subgenual Anterior Cingulate Cortex in Mood Disorders , 2008, CNS Spectrums.

[15]  B. McEwen,et al.  Sex, stress and the hippocampus: allostasis, allostatic load and the aging process , 2002, Neurobiology of Aging.

[16]  D. Murphy,et al.  What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression , 2007, Behavioural Brain Research.

[17]  C. Chiou,et al.  MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus , 2010, Pharmacology Biochemistry and Behavior.

[18]  Gerd Kempermann,et al.  The neurogenic reserve hypothesis: what is adult hippocampal neurogenesis good for? , 2008, Trends in Neurosciences.

[19]  P. Dombrowski,et al.  Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[20]  A. Young,et al.  A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder , 2005, Biological Psychiatry.

[21]  M. Irwin,et al.  Effects of sleep and sleep loss on immunity and cytokines , 2002, Brain, Behavior, and Immunity.

[22]  M. Irwin,et al.  Inflammatory Markers and Sleep Disturbance in Major Depression , 2005, Psychosomatic medicine.

[23]  M. Pîrlog,et al.  Prenatal depression and stress - risk factors for placental pathology and spontaneous abortion. , 2014, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[24]  Travis O. Bruce.  Comorbid depression in rheumatoid arthritis: Pathophysiology and clinical implications , 2008, Current psychiatry reports.

[25]  Guy M. Goodwin,et al.  Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues , 2006, Biological Psychiatry.

[26]  W. Drevets,et al.  Functional neuroimaging studies of depression: the anatomy of melancholia. , 1998, Annual review of medicine.

[27]  R. Porsolt,et al.  Behavioral despair in mice: a primary screening test for antidepressants. , 1977, Archives internationales de pharmacodynamie et de therapie.

[28]  D. Zald,et al.  Reconsidering anhedonia in depression: Lessons from translational neuroscience , 2011, Neuroscience & Biobehavioral Reviews.

[29]  R. Dantzer,et al.  From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.

[30]  C. Da Cunha,et al.  Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease , 2008, Neuroscience.

[31]  R. Wood,et al.  Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse , 2010, Behavioural Brain Research.

[32]  C. Pittenger,et al.  Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms , 2008, Neuropsychopharmacology.

[33]  K. Sagduyu,et al.  Neuropsychopharmacology: The Fifth Generation of Progress , 2002 .

[34]  I. Weaver,et al.  Maternal care, the epigenome and phenotypic differences in behavior. , 2007, Reproductive toxicology.

[35]  Andrew H. Miller,et al.  Biology of Depression and Cytokines in Cancer , 2010 .

[36]  M. Massie.  Prevalence of depression in patients with cancer. , 2004, Journal of the National Cancer Institute. Monographs.

[37]  Y. Mitsumoto,et al.  Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice , 2005, Neuroscience Research.

[38]  W. Jost,et al.  [Nonmotor symptoms in Parkinson's disease]. , 2017, Der Nervenarzt.

[39]  A. Schatzberg,et al.  Corrigendum to: Glucocorticoid antagonists in neuropsychiatric disorders [European Journal of Pharmacology 583 (2008) 358–364] , 2008 .

[40]  Andrew H. Miller,et al.  When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. , 2011, The American journal of psychiatry.

[41]  Y. Lecrubier,et al.  Dysbindin gene (DTNBP1) in major depressive disorder (MDD) patients: Lack of association with clinical phenotypes , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[42]  E. Gould,et al.  Preclinical models: status of basic research in depression , 2002, Biological Psychiatry.

[43]  Alan A. Wilson,et al.  Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. , 2006, The American journal of psychiatry.

[44]  M. Weissman,et al.  RISK FACTORS FOR MAJOR DEPRESSION AND BIPOLAR DISORDER , 2002 .

[45]  C. Lyketsos,et al.  Mood Disorders in the Medically Ill: Scientific Review and Recommendations , 2005, Biological Psychiatry.

[46]  E. Young,et al.  Sex, trauma, stress hormones and depression , 2010, Molecular Psychiatry.

[47]  A. Caspi,et al.  Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene , 2003, Science.

[48]  J. Mill,et al.  Molecular studies of major depressive disorder: the epigenetic perspective , 2007, Molecular Psychiatry.

[49]  Eric J. Nestler,et al.  New approaches to antidepressant drug discovery: beyond monoamines , 2006, Nature Reviews Neuroscience.

[50]  K. Ismail.  Unraveling the Pathogenesis of the Depression–Diabetes Link , 2010 .

[51]  G. Donnan,et al.  Motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse , 1987, Journal of the Neurological Sciences.

[52]  C. Kirschbaum,et al.  Sex Differences in Glucocorticoid Sensitivity of Proinflammatory Cytokine Production After Psychosocial Stress , 2001, Psychosomatic medicine.

[53]  J. Amsterdam,et al.  Dopamine transporter density may be associated with the depressed affect in healthy subjects , 2007, Nuclear medicine communications.

[54]  H. Anisman,et al.  Sex differences in hormonal responses to a social stressor in chronic major depression , 2009, Psychoneuroendocrinology.

[55]  Eric J. Nestler,et al.  The molecular neurobiology of depression , 2008, Nature.

[56]  R. Duman,et al.  Serum Brain-Derived Neurotrophic Factor, Depression, and Antidepressant Medications: Meta-Analyses and Implications , 2008, Biological Psychiatry.

[57]  D. Slattery,et al.  Evaluation of reward processes in an animal model of depression , 2007, Psychopharmacology.

[58]  H. Kraemer,et al.  Untreated depression and hippocampal volume loss. , 2003, The American journal of psychiatry.

[59]  A. P. Carobrez,et al.  Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on , 2005, Neuroscience & Biobehavioral Reviews.

[60]  A. Möller-Leimkühler.  Higher comorbidity of depression and cardiovascular disease in women: A biopsychosocial perspective , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[61]  P. Gorwood.  Neurobiological mechanisms of anhedonia , 2008, Dialogues in clinical neuroscience.

[62]  D. Nutt.  Relationship of neurotransmitters to the symptoms of major depressive disorder. , 2008, The Journal of clinical psychiatry.

[63]  K. Kendler.  Explanatory models for psychiatric illness. , 2008, The American journal of psychiatry.

[64]  A. Johnson,et al.  Stress, depression and cardiovascular dysregulation: A review of neurobiological mechanisms and the integration of research from preclinical disease models , 2009, Stress.

[65]  R. Coveñas,et al.  Classical Neurotransmitters and Neuropeptides Involved in Major Depression: a Review , 2010, The International journal of neuroscience.

[66]  M. Lowe,et al.  Activity and Connectivity of Brain Mood Regulating Circuit in Depression: A Functional Magnetic Resonance Study , 2005, Biological Psychiatry.

[67]  M. Opp.  Sleep and psychoneuroimmunology. , 2009, Immunology and allergy clinics of North America.

[68]  K. Kendler,et al.  Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. , 2000, The American journal of psychiatry.

[69]  B. Ravnkilde,et al.  Hippocampal volume and depression: a meta-analysis of MRI studies. , 2004, The American journal of psychiatry.

[70]  C. Nemeroff,et al.  The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. , 1998, Archives of general psychiatry.

[71]  R. Wood,et al.  Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury , 2008, Neurobiology of Disease.

[72]  T. Deak,et al.  Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat , 2010, Behavioural pharmacology.

[73]  Y. Goshima,et al.  Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism , 1990, Brain Research.